期刊文献+

Advances in therapeutics for liver metastasis from colorectal cancer 被引量:2

Advances in therapeutics for liver metastasis from colorectal cancer
下载PDF
导出
摘要 The evolution of chemotherapeutic regimens that include targeted molecular agents has resulted in a breakthrough in the management of advanced colorectal liver metastasis (CLM), improving the progression-free survival after liver resection, and rendering initially unresectable liver tumors resectable, with reported resection rates ranging from 13% to 51%. In addition, the criteria used for selecting patients for hepatectomy have been expanding because of advances in surgical techniques and improvements in chemotherapy. However, the increasing use of chemotherapy has raised concern about potential hepatotoxicities such as steatosis, chemotherapy-associated steatohepatitis, and sinusoidal obstruction syndrome, and their deleterious effects on postoperative outcome. The present review focuses on the advantages and disadvantages of chemotherapy, strategies for the prevention and diagnosis of chemotherapy-associated liver injury, and the adoption of more aggressive surgical approaches, which have changed the traditional paradigm for CLM. The evolution of chemotherapeutic regimens that include targeted molecular agents has resulted in a breakthrough in the management of advanced colorectal liver metastasis (CLM), improving the progression-free survival after liver resection, and rendering initially unresectable liver tumors resectable, with reported resection rates ranging from 13% to 51%. In addition, the criteria used for selecting patients for hepatectomy have been expanding because of advances in surgical techniques and improvements in chemotherapy. However, the increasing use of chemotherapy has raised concern about potential hepatotoxicities such as steatosis, chemotherapy-associated steatohepatitis, and sinusoidal obstruction syndrome, and their deleterious effects on postoperative outcome. The present review focuses on the advantages and disadvantages of chemotherapy, strategies for the prevention and diagnosis of chemotherapy-associated liver injury, and the adoption of more aggressive surgical approaches, which have changed the traditional paradigm for CLM.
出处 《World Journal of Gastrointestinal Oncology》 SCIE CAS 2010年第10期380-389,共10页 世界胃肠肿瘤学杂志(英文版)(电子版)
关键词 COLORECTAL liver METASTASIS Chemotherapy Hapatotoxicity MULTIMODAL therapy TARGETED biological agent Colorectal liver metastasis Chemotherapy Hapatotoxicity Multimodal therapy Targeted biological agent
  • 相关文献

参考文献112

  • 1Takeshi Takamoto MD,Takuya Hashimoto MD, PhD,Keiji Sano MD, PhD,Yoshikazu Maruyama MD,Kazuto Inoue MD, PhD,Satoshi Ogata MD, PhD,Tamiko Takemura MD, PhD,Norihiro Kokudo MD, PhD,Masatoshi Makuuchi MD, PhD.Recovery of Liver Function After the Cessation of Preoperative Chemotherapy for Colorectal Liver Metastasis[J]. Annals of Surgical Oncology . 2010 (10)
  • 2Béatrice Aussilhou MD,Safi Dokmak MD,Sandrine Faivre MD,Valérie Paradis MD,Valérie Vilgrain MD,Jacques Belghiti MD.Preoperative Liver Hypertrophy Induced by Portal Flow Occlusion Before Major Hepatic Resection for Colorectal Metastases Can Be Impaired by Bevacizumab[J]. Annals of Surgical Oncology . 2009 (6)
  • 3Charles R. Scoggins,Michael L. Campbell,Christine S. Landry,Beatrix A. Slomiany,Charles E. Woodall,Kelly M. McMasters,Robert C. G. Martin.Preoperative Chemotherapy Does Not Increase Morbidity or Mortality of Hepatic Resection for Colorectal Cancer Metastases[J]. Annals of Surgical Oncology . 2009 (1)
  • 4Daria Zorzi MD,Yun Shin Chun MD,David C. Madoff MD,Eddie K. Abdalla MD,Jean-Nicolas Vauthey MD.Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases[J]. Annals of Surgical Oncology . 2008 (10)
  • 5Timothy M. Pawlik,Kelly Olino,Ana Luiza Gleisner,Michael Torbenson,Richard Schulick,Michael A. Choti.Preoperative Chemotherapy for Colorectal Liver Metastases: Impact on Hepatic Histology and Postoperative Outcome[J]. Journal of Gastrointestinal Surgery . 2007 (7)
  • 6Peter Kornprat MD,William R. Jarnagin MD, FACS,Mithat Gonen PhD,Ronald P. DeMatteo MD, FACS,Yuman Fong MD, FACS,Leslie H. Blumgart MD, FACS, FRCS,Michael D’Angelica MD, FACS.Outcome After Hepatectomy for Multiple (Four or More) Colorectal Metastases in the Era of Effective Chemotherapy[J]. Annals of Surgical Oncology . 2007 (3)
  • 7Lorenzo Capussotti MD,Luca Vigano’ MD,Alessandro Ferrero MD,Roberto Lo Tesoriere MD,Dario Ribero MD,Roberto Polastri MD.Timing of Resection of Liver Metastases Synchronous to Colorectal Tumor: Proposal of Prognosis-Based Decisional Model[J]. Annals of Surgical Oncology . 2007 (3)
  • 8Michael D’Angelica MD,Peter Kornprat MD,Mithat Gonen PhD,Ki-Young Chung MD,William R. Jarnagin MD, FACS,Ronald P. DeMatteo MD, FACS,Yuman Fong MD, FACS,Nancy Kemeny MD,Leslie H. Blumgart MD, FACS, FRCS,Leonard B Saltz MD.Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study[J]. Annals of Surgical Oncology . 2007 (2)
  • 9Gianluca Masi MD,Samanta Cupini MD,Lorenzo Marcucci MD,Elisa Cerri MD,Fotios Loupakis MD,Giacomo Allegrini MD,Isa Maura Brunetti MD,Elisabetta Pfanner MD,Maurizio Viti MD,Orlando Goletti MD,Franco Filipponi MD,Alfredo Falcone MD.Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal Cancer[J]. Annals of Surgical Oncology . 2006 (1)
  • 10David A. Kooby M.D.,Yuman Fong M.D.,Arief Suriawinata M.D.,Mithat Gonen Ph.D.,Peter J. Allen M.D.,David S. Klimstra M.D.,Ronald P. DeMatteo M.D.,Michael D. Angelica M.D.,Leslie H. Blumgart M.D.,William R. Jarnagin M.D..Impact of steatosis on perioperative outcome following hepatic resection[J]. Journal of Gastrointestinal Surgery . 2003 (8)

共引文献30

同被引文献40

  • 1佘军军,王子明,车向明,潘承恩.β-榄香烯介入治疗兔VX2肾移植癌的实验研究[J].中西医结合学报,2006,4(6):611-614. 被引量:2
  • 2Stangl R,Altendorf-Hofmann A,Chamley RM,et al.Factors influencing the natural history of colorectal liver metastasesThe Lancet,1994.
  • 3Jemal A,Center MM,DeSantis C,Ward EM.Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiology Biomarkers and Prevention . 2010
  • 4Stéphane Benoist MD, PhD,Bernard Nordlinger MD.The Role of Preoperative Chemotherapy in Patients with Resectable Colorectal Liver Metastases[J]. Annals of Surgical Oncology . 2009 (9)
  • 5Tomlinson JS,Jarnagin WR,DeMatteo RP,Fong Y,Korn- prat P,Gonen M,Kemeny N,Brennan MF,Blumgart LH,D’’Angelica M.Actual 10-year survival after resection of colorectal liver metastases defines cure. Journal of Clinical Oncology . 2007
  • 6Simmonds P.C,Primrose J.N,Colquitt J.L,Garden O.J,Poston G.J,Rees M.Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. British Journal of Cancer . 2006
  • 7Ting Luo,Hua-Mei Yan,Ping He,Yong Luo,Yuan-Fu Yang,Hong Zheng.Aspirin use and breast cancer risk: a meta-analysis[J]. Breast Cancer Research and Treatment . 2012 (2)
  • 8Alexander T,Swistel MD,James R,et al.Intraarterial versus intravenous adrimaycin in the rabbit Vx2 tumor system. Cancer . 1984
  • 9Yu HG,Huang JA,Yang YN,et al.The effects of acetylsalicylic acid on proliferation, apoptosis, and invasion of cyclooxygenase-2 negative colon cancer cells. European Journal of Clinical Investigation . 2002
  • 10Arango H A,Icely S,Roberts W S,et al.Aspirin effects on endometrial cancer cell growth. Obstetrics and Gynecology . 2001

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部